DIANE SPEELMAN: Open Payments
NPI 1952637241 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,500 in 32 payments from 15 companies in 2025. Trend: 2023 $135 · 2024 $1,215 · 2025 $5,500
Food & beverage: $3,141Travel & lodging: $1,647Honoraria: $600Education: $112
| Company | Payments | Amount |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 7 | $2,417 |
| Janssen Biotech, Inc. | 4 | $546 |
| Gilead Sciences, Inc. | 4 | $435 |
| AstraZeneca Pharmaceuticals LP | 3 | $372 |
| Astellas Pharma Global Development | 2 | $281 |
| ABBVIE INC. | 2 | $225 |
| JAZZ PHARMACEUTICALS INC. | 1 | $150 |
| Daiichi Sankyo Inc. | 1 | $150 |
| Novartis Pharmaceuticals Corporation | 2 | $146 |
| American Regent | 1 | $145 |
Products named: MONOFERRIC, COSELA, RYBREVANT, INJECTAFER, ZIIHERA, Padcev, Xtandi, MI CANCER SEEK.
Industry payments across WA — which companies pay providers there.
